Keywords
Gastrointestinal
Obesity
Semaglutide
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze semaglutide’s physiological impacts in patients with obesity or overweight. Methods: This review used several databases, which were: Scielo, Scopus and PubMed. Articles published between 2020 and 2023 were selected using the Rayyan tool. At the end of the study, 20 articles were selected among all the findings. The inclusion criterias used were pertinence, relevance and scope of theoretical and practical approaches. Results: The use of semaglutide showed more weight loss in comparison to other counterparts. Furthermore, it was capable of maintaining weight loss after treatment and enabled a better quality of life. Nonetheless, gastrointestinal problems, which caused treatment withdrawal, along with some contraindications and important adverse effects were identified. Final considerations: It is considered therefore, despite the various adverse effects, mainly gastrointestinal, the treatment with semaglutide still was a very efficient solution for weight loss.
References
AMARO SW. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate medice, 2022; 134(0): 5-17.
CHAO AM, et al. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Drug design, development and therapy, 2022; 16: 4449-4461.
DAVIES M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England), 2021; 397(10278): 971-984.
FRIENDRICHSEN M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab, 2021; 23(3): 754-762.
GARVEY WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine, 2022; 28(10): 2038-2091.
GHUSN W, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open, 2022; 5(9): 2231982.
HU Y, et al. Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting. Annals of translational medicine, 2022; 10(3): 152.
JENSEN AB, et al. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. Obesity Surgery, 2023; 33: 1017-1025.
KNOP FK, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (Londo, England), 2023; 402 (10403): 705-719.
KOSIBOROD MN, et al. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC, 2023; 11(81): 1000-1010.
KUSHNER RF, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring, Md.), 2020; 28(6): 1050-1061.
KYRILLOS J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. The American journal of managed care, 2022; 28(15): S297-S306.
ROSENBERG K. Diabetes Drug AIDS Weight Reduction in Adults. The American journal of nursing, 2021; 121(5): 71.
RUBINO DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021; 325(14): 1414-1425.
RUBINO DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 2022; 327(2): 138-150.
TAN H, et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc, 2022; 37(2): 65-72.
VERMA S, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. eClinicalMedicine, 2023; 55: 101737.
WHARTON S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism, 2022; 24(1): 94-105.
WHARTON S, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.). 2023; 31(3): 703-715.
WILDING JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2021; 384(11): 989-1002.